|
Market Closed -
Euronext Paris
12:55:00 2026-10-28 EDT
|
5-day change | 1st Jan Change | ||
| 347.50 EUR | -0.29% |
|
+0.72% | -2.80% |
| 10-20 | Virbac: A well-done Q3 validates underlying quality |  |
| 10-20 | Virbac stock little changed despite strong update and targets now expected at the top end of the range |  |
Business description: Virbac
- pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips;
- livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc.
Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Number of employees: 6,442
Sales by Activity: Virbac
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
Companion Animals | 609M | 706M | 721M | 824M | 869M |
Farm Animals | 426M | 478M | 493M | 537M | 575M |
Other Businesses | 28.8M | 31.8M | 33.2M | 36.3M | 20.3M |
Geographical breakdown of sales: Virbac
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
Europe | - | - | - | 571M | 610M |
Latin America | 167M | 197M | 214M | 222M | 223M |
North America | 124M | 162M | 165M | 182M | 200M |
India, Africa and Middle East ("IMEA") | - | - | - | 174M | 178M |
Far East Asia | - | - | - | 141M | 154M |
Pacific | 94.19M | 118M | 116M | 108M | 101M |
Africa & Middle East | 29.7M | 32.47M | 29.67M | - | - |
Europe (Excluding france) | 281M | 303M | 327M | - | - |
Asia | 184M | 213M | 204M | - | - |
France | 185M | 192M | 192M | - | - |
Executive Committee: Virbac
| Manager | Title | Age | Since |
|---|---|---|---|
Paul Martingell
CEO | Chief Executive Officer | 46 | 2025-08-31 |
Habib Ramdani
CEO | Chief Executive Officer | 50 | 2024-09-26 |
Sophie Favini
COO | Chief Operating Officer | 64 | 2021-12-31 |
Marc Bistuer
CMP | Compliance Officer | 65 | 2022-12-31 |
| Chief Tech/Sci/R&D Officer | 63 | 2020-12-31 |
Composition of the Board of Directors: Virbac
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 61 | 2006-03-31 | |
| Director/Board Member | 68 | 2010-07-27 | |
| Director/Board Member | 65 | 2017-09-04 | |
| Director/Board Member | 32 | 2017-09-04 | |
| Director/Board Member | 56 | 2019-06-17 | |
| Director/Board Member | 61 | 2023-12-20 | |
Luc Thielland
BRD | Director/Board Member | 35 | 2023-12-31 |
Holdings: Virbac
| Name | Stocks | % | Valuation |
|---|---|---|---|
VIRBAC 0.15% | 12,836 | 0.15% | 5 M $ |
Company details: Virbac
Group companies: Virbac
| Name | Category and Sector |
|---|---|
Virbac Danmark A/S | |
Virbac Sp zoo | |
Virbac Ltd.
 Virbac Ltd. Medical DistributorsDistribution Services Wholesales pharmaceutical product |
Medical Distributors
|
Virbac (Australia) Pty Ltd.
 Virbac (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Manufactures veterinary paharmaceuticals and vaccines |
Pharmaceuticals: Major
|
Virbac Mexico SA de CV
 Virbac Mexico SA de CV Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products |
Pharmaceuticals: Major
|
Veterinary Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.29% | +0.72% | -4.01% | +28.70% | 3.25B | |
| +0.50% | +0.36% | +55.89% | +129.96% | 1,143B | |
| +0.86% | +4.50% | +42.43% | +86.15% | 647B | |
| -0.14% | -1.07% | +25.42% | +105.85% | 506B | |
| -0.05% | +2.28% | +49.14% | +67.74% | 384B | |
| -0.63% | -4.97% | +60.15% | +37.06% | 350B | |
| +0.34% | +2.15% | +25.26% | +54.27% | 293B | |
| -0.45% | +1.16% | +1.74% | +26.08% | 265B | |
| +0.87% | +2.94% | +55.18% | +72.74% | 242B | |
| +0.08% | +1.72% | +32.15% | +107.78% | 197B | |
| Average | +0.23% | +0.86% | +34.33% | +71.63% | 403.08B | |
| Weighted average by Cap. | +0.35% | +0.71% | +42.59% | +88.97% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VIRP Stock
- Company Virbac
Select your edition
All financial news and data tailored to specific country editions
